PRNewsWire
19 Mar 2026, 13:00 UTC · 26w ago
Verdict
Headline leans bearish. We score AQST −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA identified deficiencies in Aquestive Therapeutics' Anaphylm NDA that precluded labeling discussions.
More negative than 99% of claims this week
Cantor slashed its price target for AQST from $15 to $8 due to increased risk of a potential delay for Anaphylm.
So whatA nearly 50% reduction in price target by a major analyst reflects a significant loss of institutional confidence in the asset's valuation.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
A securities fraud class action lawsuit has been initiated alleging that management misled investors regarding the FDA review process.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud lawsuit following a price target slash and FDA deficiencies regarding its Anaphylm NDA.
More negative than 87% of ticker scores this week
The company is subject to a shareholder investigation after cutting forecasts shortly after maintaining them.
More negative than 87% of ticker scores this week
Investors are reporting losses after the company lowered its full-year gross-margin expectations and cut revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1d ago
+14.7%
Price is moving against the score
$4.61 vs $4.02 close before publication (Mar 18) · not market-adjusted
AQST chart →
